Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

Ilya KisterYury PatskovskyRyan CurtinJinglan PeiKatherine PerdomoZoe RimlerIryna VoloshynaMarie I SamanovicAmber R CorneliusYogambigai VelmuruguSamantha NyovanieJoseph J KimEthan TardioTamar E BaconLana Zhovtis RyersonPranil RautRosetta PedottiKathleen HawkerCatarina RaposoJessica PriestMark CabatinganRyan C WingerMark J MulliganMichelle KrogsgaardGregg J Silverman

Published in: Annals of neurology (2022)

DMTs had differential effects on humoral and cellular immune responses to SARS-CoV-2 infection. Immune responses did not correlate with COVID-19 clinical severity in this relatively young and nondisabled group of patients with MS. ANN NEUROL 2022;91:782-795.

Keyphrases

immune response
multiple sclerosis
end stage renal disease
coronavirus disease
respiratory syndrome coronavirus
dendritic cells
sars cov
toll like receptor
ejection fraction
chronic kidney disease
mass spectrometry
peritoneal dialysis
prognostic factors
ms ms
white matter
patient reported outcomes
neural network